Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Coluracetam | DMAE (Dimethylaminoethanol) | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 20-80 mg/day divided into 2-3 doses | 150-400 mg/day (as DMAE bitartrate, typically 37% DMAE) |
| Timing | Morning and early afternoon. Sublingual administration may provide faster onset. With or without food. | Morning. With or without food. |
| Cycle Duration | Cycles of 4-8 weeks on, 2-4 weeks off | Ongoing; no strict cycling required |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
Enhances high-affinity choline uptake (HACU) via a unique mechanism distinct from other racetams — it increases HACU even in damaged cholinergic neurons, suggesting a choline uptake enhancement rather than mere stimulation. This HACU enhancement persists even after the compound has been cleared, indicating a lasting modification of choline transporter activity. Also shows affinity for AMPA receptors.
20-80 mg/day divided into 2-3 doses
Morning and early afternoon. Sublingual administration may provide faster onset. With or without food.
Cycles of 4-8 weeks on, 2-4 weeks off
Structural analog of choline that crosses the BBB more readily than choline itself. Paradoxically increases choline availability not by serving as a direct precursor to acetylcholine, but by inhibiting choline metabolism in peripheral tissues, thereby increasing circulating choline available for brain uptake. Also acts as a free radical scavenger and membrane stabilizer. Reduces lipofuscin accumulation in neuronal cells, an age pigment associated with cellular aging.
150-400 mg/day (as DMAE bitartrate, typically 37% DMAE)
Morning. With or without food.
Ongoing; no strict cycling required
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →